The independent analysis provider, Praetorian Research has published their
latest update regarding aresa, and states:
A new start after the red card
aresa's Q3 results were the company's last financial results as a biotech
company. The scientific staff has been laid off,and the company is now
preparing to launch itself as an investment company. We see favourable
opportunities for
land investment in the Balkans. Investments have started,but we have yet to see
a specific plan. We therefore continue to suspend our rating of the share.
The entire analysis can be found in the attached document.
For more information, please contact Jesper Ilsøe, Praetorian Research, tlf:
5025 3000, email: info@p-research.dk
or
Steen Thaarup
CEO
Phone: +45 7022 7747
Mobile: +45 4077 8695
E-mail: st@aresa.dk
The company's certified advisor is Dahl-Sørensen & Partners A/S, Allan Reimann,
tel.: +45 3364 9205.
About Aresa
Aresa is a plant biotech company established in 2001 by the company's current
CSO, Carsten Meier. It originates from the Institute of Molecular Biology at
Copenhagen University.
Aresa focuses on the plant-based technology platform: BioSensor for the
detection of substances in soil, including leakage of explosives from landmines.
Aresa shares are traded at the Nasdaq/OMX-First North stock exchange since the
introduction in 2006. Aresa is based at Symbion Science Park in Copenhagen and
has greenhouse facilities on the outskirts of Copenhagen and test sites in
Denmark, Croatia, and Serbia. Aresa has 11 employees, 7 in research &
development and 2 in landmine operations.
